Clinuvel Pharmaceuticals stock | Price, analyst rating, price target & growth

Clinuvel Pharmaceuti...

ASX:CUV

$ 9,09

$-0,02 (-0,22%)

9,09 $

$-0,02 (-0,22%)

End-of-day quote: 04/10/2026

Clinuvel Pharmaceuticals Stock Value

Analysts currently give ASX:CUV a rating of Buy.

Buy

Clinuvel Pharmaceuticals Company Info

EPS Growth 5Y

16,89%

Market Cap

$0,46 B

Long-Term Debt

$0,00 B

Quarterly earnings

05/28/2026 (E)

Dividend

$0,05

Dividend Yield

0,55%

Founded

1999

Industry

Health Care

Country

Australia

Website

Clinuvel Pharmaceuticals

ISIN Number

AU000000CUV3

Website

http://www.clinuvel.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$22,00

142.02%

Last Update: 04/11/2026

Analysts: 7

Highest Price Target $40,50

Average Price Target $22,00

Lowest Price Target $13,00

In the last five quarters, Clinuvel Pharmaceuticals’s Price Target has fallen from $34,19 to $27,41 - a -19,83% decrease. Seven analysts predict that Clinuvel Pharmaceuticals’s share price will increase in the coming year, reaching $22,00. This would represent an increase of 142,02%.

Top growth stocks in the health care sector (5Y.)

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Limited,engages in the developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. Business Segments The company operates within a singular operating segment, focusing entirely on the biopharmaceutical sector. The company has structured its operations into four distinct divisions such as Pharmaceuticals, Healthcare Solutions, Communications Branding & Marketing, and Manufacturing. This framework allows for...

Clinuvel Pharmaceuticals Limited,engages in the developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders.

Business Segments

The company operates within a singular operating segment, focusing entirely on the biopharmaceutical sector.

The company has structured its operations into four distinct divisions such as Pharmaceuticals, Healthcare Solutions, Communications Branding & Marketing, and Manufacturing.

This framework allows for specialized management of its various operational areas, ensuring targeted efficiency and effectiveness in meeting the specific needs of its stakeholders.

Pharmaceuticals: The company division is fundamentally focused on the development of therapies rooted in the company's proprietary technologies. The primary focus here remains on the commercialization of Scenes’, with ongoing clinical trials for additional therapeutic indications. Through this division, the company also examines other photoprotective agents that can expand its portfolio and influence within the broader dermatological treatment space.

Healthcare Solutions: The company encompasses the services and support provided to patients, healthcare providers, and governments. This division works on integrating the company's product offerings into existing healthcare frameworks, advocating for access to therapies, and continuously engaging in discussions with healthcare professionals to promote medical education surrounding rare skin disorders and their management.

Communications Branding & Marketing: The company division is crucial for raising awareness about the company’s product offerings and the conditions they treat. The company employs a variety of outreach strategies, establishing itself as a reputable authority on photoprotection and skin health through educational programs targeted at both medical professionals and patients.

Manufacturing: The company products are produced to the highest standards of quality and safety. By maintaining stringent manufacturing practices, the company L guarantees that all its products comply with regulatory requirements in the regions where they are sold. This division's role is paramount in supporting the company’s commitment to delivering high-quality therapeutics that adhere to the best industry practices.

Business Strategy

The company revolves around establishing itself as a leading provider of innovative therapies for skin disorders through significant investment in research and development, robust partnerships, and strategic market positioning. The company manifests a clear focus on its lead product, while simultaneously exploring new indications to expand its therapeutic offerings.

Through the strategic focus on sustainability and corporate responsibility, the company ensures that its growth aligns with social and environmental ethics. The firm aims to balance profitability with the wider implications of its actions, establishing itself as a company that not only seeks financial success but also contributes positively to its communities and the planet.

Products and Services

The company primarily offers innovative treatments in the field of dermatology, with its flagship product being, which is valued for its ability to mitigate the effects of UV exposure in patients with erythropoietic protoporphyria (EPP). Through the commercial availability, the company effectively addresses the unmet needs of EPP patients, who traditionally have faced significant limitations in sun exposure due to their condition.

Additionally, the company is diversifying its portfolio by developing supplementary products under the CUVAPIXEL line, which targets other photodermatoses and conditions related to light sensitivity. The innovation behind these products centers on the dual facets of photoprotection and skin health restoration, employing the latest advancements in dermatological science.

Beyond product offerings, the company provides comprehensive educational resources and support services designed to empower both healthcare providers and patients with the necessary information to manage skin conditions effectively. This includes engaging health professionals through training sessions and workshops, ensuring that best practices in treating rare skin disorders are widely disseminated.

The company actively participates in research studies that explore new treatment paradigms and enhance scientific understanding of skin biology. Such endeavors aid in refining the efficacy and safety profiles of its existing products and contribute to the overall body of knowledge surrounding photoprotection and dermatology.

The company’s commitment to research and development propels its mission, focusing on innovative results that translate to improved patient outcomes, ultimately transforming the landscape of care for individuals living with skin conditions.

Geographical Markets

Recent Acquisitions has established itself in various geographical markets, most notably within Europe and the United States, where it has achieved significant commercial sales. The company effectively navigates international markets to ensure compliance with local regulations while promoting the availability of its leading product.

Recent Acquisitions

In the recent past, the company has made strategic investments to enhance its operational capabilities. Notably, in July 2023, the company acquired a commercial property located in Egham, UK, which serves to accommodate its expanding workforce within Europe, reflecting its commitment to growth in the region. This acquisition symbolizes a proactive approach to meeting burgeoning demand and providing the necessary infrastructure to support its initiatives.

Seasonality

The company operates within the biopharmaceutical sector, it experiences fluctuations in its business that may relate to broader market dynamics rather than specific seasonal patterns. Sales activities related to its flagship product, , are influenced by regulatory approvals and market penetration strategies rather than seasonal variations.

Additionally, the biopharmaceutical landscape is characterized by longer development cycles for products, given the stringent requirements for clinical trials and regulatory compliance. Consequently, the company’s revenue may not exhibit pronounced seasonal trends as seen in consumer goods sectors. Instead, the timing of product launches, clinical trial results, and market acceptance are the principal factors that impact financial performance.

Customers

The company primarily consists of healthcare providers, specialty pharmacies, hospitals, and patients dealing with skin conditions that the company’s products address. A significant portion of the customer base is comprised of those affected by erythropoietic protoporphyria (EPP), for whom offers a groundbreaking therapeutic solution.

Trade Names

The company maintains several trade names associated with its product offerings, including the prominent brand. The management of these trade names involves continual review to ensure they are protected and aligned with the company's strategic branding efforts.

The company holds a robust portfolio of intellectual property rights, including patents underlying its leading product and various aspects of its pharmacological innovations. This portfolio strategically positions to protect its proprietary technologies in competitive markets.

While the specific number of trade names and patents managed by vary, the company actively enforces its intellectual property to safeguard its innovations and ensure competitive advantage. As of the latest assessments, ongoing monitoring and compliance checks ensure adherence to patent laws, thus preserving the integrity of the company's intellectual property for sustained success.

Sales and Marketing

The company employs a multi-faceted approach to sales and marketing that integrates education, stakeholder engagement, and strategic distribution channels. Through these targeted initiatives, the company aims to raise awareness about its therapeutic offerings while ensuring that patients and healthcare providers have ready access to its products.

Sales efforts are primarily directed toward healthcare professionals and institutions that specialize in dermatology and rare diseases. The company conducts workshops, symposiums, and training programs aimed at educating physicians about the benefits and applications of in treating phototoxicity due to EPP. This proactive outreach ensures that healthcare providers are well-versed in the product and its importance, ultimately facilitating patient access to necessary treatments.

The distribution of the company’s products relies on efficient partnerships with specialty pharmacies and healthcare institutions that are equipped to manage the unique requirements of the biopharmaceutical sector. Distribution channels are strategically chosen to enhance the reach of and other potential products, ensuring that they are available to patients who need them most.

The company marketing and sales strategies reflect a commitment to education, access, and patient-centric values that align with its mission to provide effective solutions for those affected by rare skin disorders.

Government Regulations

The company operates within a highly regulated industry, under strict governmental oversight to ensure compliance with laws governing drug development, manufacturing, and distribution. The company is subject to the regulations set forth by bodies such as the Therapeutic Goods Administration (TGA) in Australia, the Food and Drug Administration (FDA) in the United States, and various regulatory authorities across Europe.

History

Clinuvel Pharmaceuticals Limited, was incorporated in 1999.

Clinuvel Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - **Pharmaceutical products:** 70% - **Dermatology:** 20% - **Research and development:** 10% **TOP 3 Markets:** - **USA:** 40% - **Europe:** 35% - **Australia:** 15% Clinuvel Pharmaceuticals Limited generates the majority of its revenue from the pharmaceutical...

At which locations are the company’s products manufactured?

**Production Sites:** No specific information available (as of 2026) Clinuvel Pharmaceuticals Limited is a specialized pharmaceutical company that focuses on the development of therapies for rare diseases. The company is known for its research and development activities, particularly in the field o...

What strategy does Clinuvel Pharmaceuticals pursue for future growth?

**Focus on Product Diversification and Geographic Expansion** **Investments in Research and Development** **Strengthening Market Presence in the USA and Europe** Clinuvel Pharmaceuticals Limited pursues a strategy aimed at product diversification and geographic expansion. The company plans to e...

Which raw materials are imported and from which countries?

I'm sorry, I do not have specific information about the commodities or materials that Clinuvel Pharmaceuticals Limited imports in 2026, as well as their countries of origin. Clinuvel Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for photoprotection...

How strong is the company’s competitive advantage?

**Market share in phototherapy:** 40% (2025, estimate) **Research & development expenses:** 25% of revenue (2025) Clinuvel Pharmaceuticals Limited has a significant competitive advantage in the field of phototherapy, especially through their specialized treatment of light sensitivity disorders....

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated for 2026) **Insider Buys/Sells:** No significant transactions in the last year (2025) The institutional investor share in Clinuvel Pharmaceuticals Limited is estimated to be around 45%. This suggests that a considerable number of shares are held by...

What percentage market share does Clinuvel Pharmaceuticals have?

**Market share of Clinuvel Pharmaceuticals Limited:** Estimated 5% (2026) **Top competitors and their market share:** 1. **Johnson & Johnson:** 15% 2. **Pfizer:** 12% 3. **Novartis:** 10% 4. **Roche:** 8% 5. **Sanofi:** 7% 6. **GlaxoSmithKline:** 6% 7. **Clinuvel Pharmaceuticals Limited:** 5% 8...

Is Clinuvel Pharmaceuticals stock currently a good investment?

**Revenue Growth:** 18% (2025) **Research and Development Expenses:** 25% of Revenue (2025) **Market Expansion:** New Approvals in North America and Asia (2025) Clinuvel Pharmaceuticals Limited recorded a revenue growth of 18% in 2025, attributed to the successful launch of new products and expansi...

Does Clinuvel Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend payment:** Yes, Clinuvel Pharmaceuticals pays a dividend. **Dividend yield:** 1.8% (2026) **Dividend history:** Regular payouts since 2021. Clinuvel Pharmaceuticals has started paying a dividend in recent years, indicating a positive financial development and stable cash flows. The d...

New support ticket

Explore

Clinuvel Pharmaceuticals Stock Value

Clinuvel Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Clinuvel Pharmaceuticals Stock Value

Clinuvel Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.